Geopolitical Risks Threaten Pharma Supply Chains in 2026

Geopolitical Turbulence: A New Operating Reality for Pharma Supply Chains

Pharmaceutical supply chains face an inflection point in 2026, according to DSV's forward-looking analysis. For decades, the industry has optimized for cost efficiency and just-in-time delivery, building networks that depend on stable, predictable geopolitical conditions. That era is ending. Rising regional tensions, trade policy uncertainty, and the weaponization of supply chains mean that pharmaceutical companies must fundamentally rethink their operational playbooks—moving from cost optimization to resilience-first network design.

The stakes could not be higher. Pharmaceuticals are critical infrastructure: disruptions don't just affect corporate margins—they impact patient outcomes, public health systems, and government policies. Unlike consumer goods, which can tolerate delays, medicines cannot. A manufacturing interruption in a key supplier region, a sudden export ban, or a logistics corridor closure can create drug shortages within weeks. DSV's assessment signals that supply chain leaders must treat geopolitical risk with the same rigor they apply to demand forecasting and capacity planning.

Why 2026 Matters: The Convergence of Structural Pressures

Several factors converge to make 2026 a critical juncture for pharmaceutical supply chains. First, the industry's heavy dependence on a small number of supplier countries—particularly China and India for active pharmaceutical ingredients (APIs)—creates concentration risk. Second, ongoing trade tensions and sanctions regimes are becoming normalized rather than temporary shocks, forcing permanent network recalibration. Third, new regulatory pressures around supply chain transparency, particularly in Europe and North America, mean companies can no longer operate with opaque, multi-tier supplier networks. Finally, the cold-chain logistics requirements for newer therapies (biologics, mRNA vaccines) add another layer of complexity and vulnerability.

For supply chain professionals, this means the comfortable assumptions of the last 15 years no longer hold. Dual-sourcing, once seen as a costly luxury, is now a strategic imperative. Nearshoring, historically dismissed as uncompetitive, is increasingly justified by risk reduction and supply chain visibility. Inventory buffers, long minimized to reduce working capital, must be reconsidered for critical drugs where stockouts create humanitarian crises.

Operational Implications: From Reaction to Prediction

The shift from reactive to proactive supply chain management requires new capabilities. First, companies need real-time geopolitical monitoring: dedicated teams tracking policy changes, regional conflicts, and trade dynamics that could disrupt supply. This is not abstract risk assessment—it's operational intelligence tied directly to sourcing decisions and contingency planning. Second, supply chain networks must be stress-tested against specific geopolitical scenarios: What happens if a key port becomes inaccessible? If sanctions target a supplier country? If air freight corridors close?

Third, logistics strategies must diversify. Heavy reliance on single routes—such as the Asia-Europe corridors via the Suez Canal or overland routes through Central Asia—creates fragility. Building redundancy into transportation, even at higher cost, is now a legitimate business case. Fourth, cold-chain logistics providers must be selected not only for technical capability but for geopolitical resilience: the ability to operate across multiple regions, navigate regulatory complexity, and maintain service during disruptions.

The Path Forward: Strategic Imperatives

Pharmaceutical supply chain leaders should act on three fronts immediately. First, conduct a comprehensive geopolitical risk audit of current suppliers, manufacturing partners, and logistics corridors. Score each link in the chain by its exposure to political volatility, trade restrictions, and regional conflict. Second, develop nearshoring strategies for critical APIs and finished products, even if initial unit costs are higher. The risk premium now justifies the investment. Third, build visibility and flexibility into contracts with suppliers and logistics partners—including force-majeure clauses that account for geopolitical disruptions, and service-level agreements that reward rapid alternative routing.

The pharmaceutical industry's resilience in 2026 will depend not on cost minimization, but on supply chain agility and geopolitical awareness. Companies that move early to build redundancy, diversify sourcing, and embed risk monitoring into their operational DNA will emerge stronger. Those that delay will face repeated crises—and the patient consequences that follow.

Source: DSV